Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

mitoguazone

A guanylhydrazone with potential antineoplastic activity. Mitoguazone competitively inhibits S-adenosyl-L-methionine decarboxylase (SAMD), an enzyme involved in the synthesis of polyamines, resulting in decreased proliferation of tumor cells, antimitochondrial effects, and p53-independent apoptosis. Polyamines, specifically spermine and spermidine, are essential for thymidine kinase production, DNA synthesis, and cell proliferation.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:methylglyoxal bisguanylhydrazone
mitoguazone dihydrochloride
pyruvaldehyde bis(amidinohydrazone)
Foreign brand name:Zyrkamine
Abbreviation:MeGAG
methyl-G
methyl-GAG
MGBG
MGGH
Code name:DRG-0223
NSC 32946
Chemical structure:1,1'-[(methylethanediylidene)dinitrilo)diguanidine
2,2"-(methyl-1,2-ethanediylidene)bis[hydrazinecarboximidamide]
methylglyoxal bis(amidinohydrazone)
IND number:927
NSC code:32946
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search